Sylvester Comprehensive Cancer Center, University of Miami | Strategic Alliance Partners

January 16, 2020

Matthew P. Schlumbrecht, MD, discusses remaining challenges in uterine leiomyosarcoma.

January 14, 2020

A. Craig Lockhart, MD, MHS, professor and associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses investigational strategies targeting the RAS/RAF/MEK/ERK pathway in colorectal cancer (CRC).

January 13, 2020

Matthew P. Schlumbrecht, MD, discusses the role of surgical resection in uterine leiomyosarcoma.

January 10, 2020

A. Craig Lockhart, MD, MHS, discusses ongoing developments and the future of immunotherapy in colorectal cancer.

January 09, 2020

Matthew P. Schlumbrecht, MD, discusses ongoing challenges in diagnosing uterine leiomyosarcoma.

January 07, 2020

A. Craig Lockhart, MD, MHS, discusses the current treatment landscape of pancreatic cancer and how the introduction of olaparib in the frontline maintenance setting may benefit patients.

January 04, 2020

A. Craig Lockhart, MD, MHS, professor, associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses next steps for regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) in metastatic colorectal cancer (mCRC).

December 02, 2019

The director of Sylvester Comprehensive Cancer Center is named the first holder of the Oscar de la Renta Endowed Chair in Cancer Research.

July 30, 2019

Sylvester Comprehensive Cancer Center, part of the University of Miami Leonard M. Miller School of Medicine, has received the prestigious NCI designation from the National Cancer Institute.

June 26, 2019

Anlotinib, a novel tyrosine kinase inhibitor capable of mounting a multipronged attack against oncogenic processes, is being tested in rare soft tissue sarcoma subtypes where patients have limited therapeutic options.

May 09, 2019

Matthew P. Schlumbrecht, MD, associate professor and co-director of Cancer Prevention and Control, Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses investigational treatment strategies in uterine leiomyosarcoma.

April 12, 2019

James E. Hoffman, MD, assistant professor of clinical medicine at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses remaining challenges in the field of relapsed/refractory myeloma.

April 12, 2019

Craig Moskowitz, MD, physician-in-chief, Oncology Service Line, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the use of PET-adapted therapy in the treatment of patients with advanced-stage Hodgkin lymphoma.

April 08, 2019

Juan P. Alderuccio, MD, discusses the current state of the treatment paradigm in multiple myeloma and ongoing challenges that remain.

April 03, 2019

Joseph D. Rosenblatt, MD, discusses how advances made in chronic lymphocytic leukemia are changing the outlook for patients and predicts what can be accomplished in the near future.

March 30, 2019

Terrence J. Bradley, MD, assistant professor, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami in Health System, discusses the use of ruxolitinib (Jakafi) in the treatment of patients with myeloproliferative neoplasms (MPNs).

March 06, 2019

Mohammad Jahanzeb, MD, shares the challenges of real-world eligibility for immunotherapy in lung cancer and beyond.

December 12, 2018

Vivek Venkatramani, MD, and Dipen J. Parekh, MD, discuss the evolution of surgery in bladder cancer.

June 07, 2018

Frances Valdes-Albini, MD, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses ongoing clinical trials of patients with HER2-positive breast cancer.

April 26, 2018

Reshma L. Mahtani, DO, discusses the use of adjuvant endocrine therapy in premenopausal breast cancers, specifically the use of ovarian function suppression and GnRH agonists.